Takeda

New Structure of Business Operations for a Global Pharmaceutical Company

TakedaAs part of its "Transformation into a New Takeda", Takeda Pharmaceutical Company Limited ("Takeda") has implemented several strategies to realize its corporate vision of achieving "sustainable growth" by 2015 through "innovation" and "culture". The latest development came with the recent closing of the Nycomed acquisition, whereby Takeda took another significant step towards globalization. Today, Takeda announces the establishment of the positions of Chief Medical & Scientific Officer (CMSO) and Chief Commercial Officer (CCO), to strengthen the company's governance and business operations as it moves forward to fully integrate the Nycomed organization and become a truly global pharmaceutical company.

In order to further strengthen its global research and development activities, Takeda has abolished the position of Chief Scientific Officer and established the new position of CMSO. Takeda board member Dr. Tadataka Yamada, a medical doctor and scientist with vast global experience in pharmaceutical R&D, has been appointed CMSO to boost research and development productivity by driving innovation and skillfully allocating resources.

In addition, the positions of International Operations (Americas/Europe) and International Operations (North Asia) have been abolished to be replaced by the CCO, who will preside over Takeda's global sales structure (with the exclusion of Millennium and Japanese domestic sales), including most former Nycomed countries and functions. Takeda has appointed board member Dr. Frank Morich as CCO, who has extensive experience at top management in the global pharmaceutical industry. Dr. Morich will drive sales strategies in the important US and EU markets, and also in the fast-growing emerging markets.

Takeda is continually challenging itself to create innovative medicines that transform treatment paradigms to prevent and cure disease, focusing particularly on fields with unmet medical needs, and will continue to globalize its business to deliver its products to patients and health care providers worldwide.

Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.

Most Popular Now

World's first public dengue immuniz…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today that the first public dengue immunization program has started in the Philippines. At a major l...

Read more

NIH launches large clinical trials …

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the A...

Read more

AstraZeneca and Eli Lilly and Compa…

AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in...

Read more

Saxenda® demonstrated significant i…

Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at th...

Read more

Vitamin D improves heart function, …

A daily dose of vitamin D3 improves heart function in people with chronic heart failure, a five-year University of Leeds research project has found. Dr Klaus Witte, from ...

Read more

Pfizer announces termination of pro…

Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The deci...

Read more

New analysis shows only minority of…

Boehringer Ingelheim has announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not ...

Read more

Researchers open the way to new tre…

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length struc...

Read more

Implantable device targets pancreat…

Pancreatic cancer is the third leading cause of cancer deaths in the United States, in part because it is very difficult for chemotherapy drugs to reach the pancreas, whi...

Read more

Physicians' knowledge about FDA app…

Since 2012, the FDA can designate a drug as a "breakthrough therapy" if preliminary clinical evidence - such as an improvement in a pharmacodynamic biomarker - suggests a...

Read more

Global spending on health is expect…

Global inequities in health spending are expected to persist and intensify over the next 25 years, according to a new study that estimates total health financing in count...

Read more

Americans live longer but with disa…

Americans are living longer but in poorer health, according to a new study. The USC-led study examined life expectancy trends and disability rates in a 40-year period, fr...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]